Indegene, an India-based communications solution company, announced that it has purchased MedCases, the CME portion of the MedCases/IC Axon tie-up.
Indegene purchased MedSN last year.
The interactive development space is competitive and challenging. Custom development, in particular, is very labor-intensive and costly, particularly in a regulated environment (such as pharma) where multiple levels of review slow down the process of getting anything done. One way of trying to make it profitable is to have a major footprint in the United States, while moving some levels of development offshore.
It will be interesting to see what impact this type of consolidation will have on smaller, boutique development shops.
Indegene’s model will not work. Demonstrably it doesn’t work in AP where the value of the English language is understood and considered as important as in Europe as a vessel for key messaging. This cannot be done in Bangalore.